[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100200817":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":16,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Dianna Howard, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":7,"phoneExt":7,"email":15},"CONTACT","dhoward@wakehealth.edu",[17],{"facility":18,"status":19,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Wake Forest Baptist Health","RECRUITING","Winston-Salem","North Carolina","27157","United States",{"type":25,"coordinates":26},"Point",[27,28],-80.24422,36.09986,{"lat":28,"lon":27},[31,35],{"name":32,"role":14,"phone":33,"phoneExt":7,"email":34},"David Hurd, MD","336-716-2843","dhurd@wakehealth.edu",{"name":32,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100200817",false,"NCT01890486","The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","The Prospective Collection, Storage and Reporting of Data on Patients","Inclusion Criteria:\n\nPlanned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant\n\nExclusion Criteria:\n\nParticipation in any other treatment research protocol","ALL","18 Years","120 Years",{"count":48,"type":49},2000,"ESTIMATED","1 Year","OBSERVATIONAL","To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.",[54,55,56,57,58,59,60,61,62,63],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Non-Hodgkin's Lymphoma","Hodgkin's Disease","Multiple Myeloma","Germ Cell Neoplasms","Myelodysplastic Syndromes","Chronic Lymphocytic Leukemia","Immunodeficiency Diseases","2026-04-09",{"date":66,"type":67},"2026-04-13","ACTUAL",{"date":69,"type":67},"2001-05-21",{"date":71,"type":49},"2026-12",{"name":5,"class":6},1]